quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:44:24·7h
SECFiling
Natera Inc. logo

SEC Form DEF 14A filed by Natera Inc.

NTRA· Natera Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • NTRA
    Natera Inc.
    Health Care

Recent analyst ratings

  • Apr 14UpdateWilliam Blair-
  • Jan 7UpdateCitigroup$300.00
  • Dec 2UpdateMorgan Stanley$265.00
  • Oct 27UpdateBNP Paribas Exane$172.00
  • Sep 22UpdateWells Fargo$175.00
  • Mar 13UpdateRBC Capital Mkts$251.00

Related

  • SEC6h
    SEC Form DEFA14A filed by Natera Inc.
  • INSIDER2d
    SEC Form 4 filed by Sheena Jonathan
  • ANALYST9d
    William Blair initiated coverage on Natera
  • PR10d
    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
  • INSIDER14d
    SEC Form 3 filed by new insider Rubin Eric H
  • PR14d
    Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
  • INSIDER15d
    SEC Form 4 filed by Rabinowitz Matthew
  • PR16d
    20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022